Inhibrx Stock (NASDAQ:INBX)
Previous Close
$15.08
52W Range
$10.80 - $18.95
50D Avg
$13.54
200D Avg
$14.08
Market Cap
$237.55M
Avg Vol (3M)
$144.38K
Beta
2.88
Div Yield
$0.85 (5.18%)
INBX Company Profile
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
INBX Performance
Peer Comparison
Ticker | Company |
---|---|
DICE | DICE Therapeutics, Inc. |
VRDN | Viridian Therapeutics, Inc. |
IKNA | Ikena Oncology, Inc. |
MRUS | Merus N.V. |
LRMR | Larimar Therapeutics, Inc. |
MLYS | Mineralys Therapeutics, Inc. |
STOK | Stoke Therapeutics, Inc. |
LYEL | Lyell Immunopharma, Inc. |
KRON | Kronos Bio, Inc. |
CRNX | Crinetics Pharmaceuticals, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
DSGN | Design Therapeutics, Inc. |
HOWL | Werewolf Therapeutics, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
PTGX | Protagonist Therapeutics, Inc. |
CELC | Celcuity Inc. |
MACK | Merrimack Pharmaceuticals, Inc. |
OPT | Opthea Limited |
ELVN | Enliven Therapeutics, Inc. |
ELYM | Eliem Therapeutics, Inc. |